Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Accumulated Expenses (2016 - 2020)

Akebia Therapeutics (AKBA) has disclosed Other Accumulated Expenses for 4 consecutive years, with $10.3 million as the latest value for Q1 2020.

  • On a quarterly basis, Other Accumulated Expenses rose 4980.69% to $10.3 million in Q1 2020 year-over-year; TTM through Mar 2020 was $10.3 million, a 4980.69% increase, with the full-year FY2019 number at $725000.0, down 81.7% from a year prior.
  • Other Accumulated Expenses was $10.3 million for Q1 2020 at Akebia Therapeutics, up from $725000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $12.8 million in Q2 2019 to a low of $40000.0 in Q3 2018.
  • A 4-year average of $3.9 million and a median of $2.4 million in 2017 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 98.24% in 2018, then surged 21807.5% in 2019.
  • Akebia Therapeutics' Other Accumulated Expenses stood at $2.4 million in 2017, then skyrocketed by 67.24% to $4.0 million in 2018, then crashed by 81.7% to $725000.0 in 2019, then surged by 1315.59% to $10.3 million in 2020.
  • Per Business Quant, the three most recent readings for AKBA's Other Accumulated Expenses are $10.3 million (Q1 2020), $725000.0 (Q4 2019), and $8.8 million (Q3 2019).